Scientific publications

Here we provide for download scientific publications released at congresses in which Orion is participating or in other contexts. 

  Congress/publication Date Available materials
 

2nd European Cancer Epigenetics Conference, Heidelberger Germany

11-13 May, 2017

Targeting cancer with a novel BET bromodomain inhibitor

  AACR Annual Meeting Washington DC, USA  1-5 April, 2017  Targeting cancer with a novel BET bromodomain inhibitor
 

AACR Annual Meeting Washington DC, USA

 

1-5 April, 2017

 Immune-mediated anti-tumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models
 

2017 Genitourinary Cancers Symposium (ASCO GU) Orlando, Florida, USA

 Feb 16-18, 2017

 ASCO GU 2017 ODM-204 Poster Fizazi et al
 

Cholangiocarcinoma Foundation Annual Conference, Salt Lake City, Utah, USA

Feb 1-3, 2017 Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumours
 

EORTC-NCI-AACR Symposium, Munich, Germany

 Nov
29 – Dec 2, 2016
 ODM-207, a novel BET-bromodomain inhibitor as a therapeutic approach for the treatment of patients with castration resistant prostate cancer
 

ESMO 2016
Copenhagen, Denmark

 

7-11
October
2016

ODM-203, phase I study poster

  ERS International Congress, London, United Kingdom  3-7 September 2016

A single dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients

  ERS International Congress, London, United Kingdom  3-7 September 2016

Budesonide/formoterol Easyhaler®: Dose consistency under simulated real-life conditions

 

  ASCO
Annual Meeting 2016,
Chicago, IL, USA

 

 June
3—7 June 2016       
ODM-203 dose escalation study poster
  European Urology Vol 69, Issue 5

May 2016

 

Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: An Open-label Phase 1 Study

  European Urology Focus

2016

Bone Scan Index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study

 

AACR Annual Meeting
New Orleans, USA

16-20 Apr
2016

ODM-207 nonclinical poster 2016 Björkman et al

 

14th International Congress on Targeted Anticancer Therapies, TAT 2016
Washington DC, USA

 

21-23 Mar
2016

ODM-2013 dose escalation study poster

 

 EAU16 Annual Congress        Munich Germany
             

 11-15 Mar 2016

Updated long-term efficacy and safety of androgen 

 

 2016 Genitourinary Cancers Symposium (ASCO GU) San Francisco, California, USA

 7-9 Jan 2016

 

 ASCO GU 2016 poster Oksala et al

 

 ICPE, Boston, USA

 22-26 Aug 2015

 A multinational, drug utilisation study to investigate the use of dexmedetomidine (Dexdor) in clinical practice in the EU

 

ERS International Congress Amsterdam, Netherlands

 26-30 Sept 2015

In vitro comparison of dose accuracy of two budenoside/formoterol dry powder inhalers
 

Expert review of Anticancer Therapy Vol 15, Issue 9

Aug 2015

ODM-201: a new-generation androgen receptor inhibitor in
castration-resistant prostate cancer
 

Scientific Reports

3 July 2015

Discovery of ODM-201, a newgeneration
androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies

 

 AACR Annual Meeting 2015 Philadelphia, Pennsylvania, USA

 18-22 April 2015

 ODM-203 nonclinical poster Holmström et al 2015

 

30th Anniversary EAU
Congress Madrid, Spain

 20-24 March 2015

 

ODM-201 ARADES and ARAFOR poster
Massard et al 2015

 

 J Aerosol Med Pulm Drug Deliv.

 March 2015

Equivalent Lung Dose and Systematic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler. Lähelmä et al 2015 

 

2015 Genitourinary Cancers Symposium (ASCO GU) Orlando, Florida, USA

26-28 February 2015

ODM-201 ARAFOR trial poster Massard et al 2015

ODM-204 nonclinical poster Oksala et al 2015

 

Movement Disoders

January 2015

Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease. Korhonen et al 2015

 

26th EORTC-NCI-AACR Symposium, Barcelona, Spain 

18-21 November 2014

ODM-203 nonclinical poster Holmström et al 2014   

 

J Aerosol Med Pulm Drug Deliv. 

 October 2014

 Evaluation of in vitro and in vivo flow rate dependency of budesonide/formoterol Easyhaler. Malmberg et al 2014

 

World Journal of Clinical Oncology

August 2014

Toremifene in the treatment of breast cancer. Mustonen et al 2014

 

The Lancet Oncology

August 2014

Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Fizazi et al 2014

 

ESMO 2014
Madrid, Spain

September 26-30, 2014 ODM-201 BSI data poster Jones et al
  29th Annual EAU Congress
Stockholm, Sweden
April 11-15, 2014 ODM-201 ARADES and ARAFOR trials poster
  AACR Annual Meeting 2014
San Diego, California, USA
April 5-9, 2014 ODM-201 nonclinical poster 
  2014 Genitourinary Cancers Symposium (ASCO GU)
San Francisco, California, USA
Jan 30- Feb 1, 2014 ODM-201 poster Massard et al 2014
ODM-201 poster Garcia et al 2014
ODM-201 poster Shore et al 2014
  The European Cancer Congress 2013
Amsterdam, Netherlands
September 2013 ODM-201 abstracts 2853 and 2869 (on ECCO website)
Summary of ODM-201 ARADES trial presentation
ODM-201 ARADES trial poster
  XXI World Congress of Neurology ( WCN)
Vienna, Austria
September 2013 STRIDE-PD poster
  17th International Congress of Parkinson’s Disease and Movement Disorders
Sydney, Australia
June 2013 ODM-101 poster
  65th AAN Annual Meeting
San Diego, California
March 2013 ORM-12741 poster
  ASCO GU
Orlando, Florida
February 2013 ODM-201 poster 
  ESMO
Vienna, Austria
September-October 2012 ODM-201 poster of the ARADES trial
ODM-201 abstract of the ARADES trial (on ESMO website)